

P26508.A03.doc

**Rec'd PCT/PTO 30 SEP 2005****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Darko FILIC et al.

Examiner : Not Known

Appln. No. : 10/521,609

Group Art Unit : Not Known

I.A. Filed : July 7, 2003

For : PROCESS FOR THE PREPARATION OF MODIFICATION I OF N-(1-METHYLETHYLAMINO-CARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDINESULFONAMIDE

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification, the International Search Report, and the International Preliminary Examination Report issued in connection with counterpart International Application No. PCT/HR2003/000036. Copies of the International Search Report (in English), and the International Preliminary Examination Report (in English) were enclosed with the papers when entering the National Stage on January 18, 2005. The Examiner is invited to review these materials to inspect the relevance indicated during international examination with respect to the documents cited therein.

P26508.A03.doc

U.S. Patent No. 4,018,929;

U.S. Patent No. 4,743,693, and its family members U.S. Patent No. 4,822,807,  
Re. 34,580 and Re. 34,672 listed in the Annex to the International Search Report;

U.S. Patent No. 5,914,336;

U.S. Patent No. 6,166,045;

DT 2516025 A1;

WO 00/20395 A1, and its family members U.S. Patent No. 6,399,637 B1 and US  
2002/147346 A1 listed in the Annex to the International Search Report;

WO 01/10441 A1, and its family member U.S. Patent No. 6,465,496 B1 listed in  
the Annex to the International Search Report;

WO 01/70694 A1;

WO 01/87841 A1;

DuPont et al., Acta Cryst. B34 (1978), 1304-1310;

DuPont et al., Acta Cryst. B34 (1978), 2659-2662;

Danilovski et al., Croatica Chemica Acta 74(1) 103-120 (2001); and

Rollinger et al., European Journal of Pharmaceutics and Biopharmaceutics, Vol.  
53, No. 1 (2002) 75-86.

In accordance with 37 C.F.R 1.98, copies of the U.S. patents and U.S. published  
patent applications are not enclosed herewith. However, if any copies are needed, the  
Examiner is respectfully requested to contact the undersigned.

Copies of the above-noted documents, except for U.S. Patents and U.S. Patent  
Publications, are enclosed together with a duly completed Form PTO-1449. The  
Examiner is accordingly requested to consider each of these documents, and to make

P26508.A03.doc


them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that while this Information Disclosure Statement is being filed more than three months from the filing date, Applicants have not received an action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed document is required under 37 C.F.R. 1.97(b)(3).

However, if an action on the merits has been mailed prior to the filing date of this Information Disclosure Statement, Applicants hereby authorize the charging of any required fees necessary for consideration of the documents cited herein to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,  
Darko FILIC et al.



Neil F. Greenblum  
Reg. No. 28,394

Arnold Turk  
Reg. No. 33,094

September 30, 2005  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191

FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P26508Application No.  
10/521,609INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

Applicant  
Darko FILIC et al.Filing Date  
I.A. Filed July 7, 2003Group  
Not Known

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4 0 1 8 9 2 9	04/19/77	DELARGE et al.			
		4 7 4 3 6 9 3	05/10/88	TOPFMEIER et al.			
		4 8 2 2 8 0 7	04/18/89	TOPFMEIER et al.			
		R e 3 4 5 8 0	04/05/94	TOPFMEIER et al.			
		R e 3 4 6 7 2	07/26/94	TOPFMEIER et al.			
		5 9 1 4 3 3 6	06/22/99	DRECKMANN-BEHRENDT			
		6 1 6 6 0 4 5	12/26/00	DRECKMANN-BEHRENDT et al.			
		6 3 9 9 6 3 7	06/04/02	FILIC et al.			
	2002 /	0 1 4 7 3 4 6	10/10/02	FILIC et al.			
		6 4 6 5 4 9 6	10/15/02	ARONHIME et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
		2 5 1 6 0 2 5	11/06/75	GERMANY				
	0	0 / 2 0 3 9 5	04/13/00	W.I.P.O.				
	0	1 / 1 0 4 4 1	02/15/01	W.I.P.O.				
	0	1 / 7 0 6 9 4	09/27/01	W.I.P.O.				
	0	1 / 8 7 8 4 1	11/22/01	W.I.P.O.				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	DuPont et al., Acta Cryst. B34 (1978), 1304-1310.
	2	DuPont et al., Acta Cryst. B34 (1978), 2659-2662.
	3	Danilovski et al., Croatica Chemica Acta 74(1) 103-120 (2001).
	4	Rollinger et al., European Journal of Pharmaceutics and Biopharmaceutics, Vol. 53, No. 1 (2002) 75-86.

EXAMINER

/Zinna Davis/ (05/29/2008)

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/ (05/29/2008)